ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1502

Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams

Evan Siegel1, Amit Garg2, Jeffrey Carter3, Laura Simone4 and Marykate Nelson5, 1Georgetown University School of Medicine, Washington, DC, 2Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, 3PRIME Education, Boynton Beach, FL, 4PRIME Education, Omaha, NE, 5PRIME Education, Drexel Hill, PA

Meeting: ACR Convergence 2022

Keywords: Psoriatic arthritis, Surveys

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The optimal care of psoriatic arthritis (PsA) requires effective collaboration between rheumatology and dermatology teams. We executed an initiative to identify gaps and inform team-based improvements in PsA co-management.

Methods: Surveys on clinical practice trends and challenges were administered to 14 clinical teams (7 rheumatology and 7 dermatology practices, which were regionally paired). The paired rheumatology and dermatology teams then engaged in an interactive educational session, led by expert faculty, to review their survey data and set action plans.

Results: Surveys were completed by 41 rheumatology healthcare professionals (HCPs) (32% physicians) and 66 dermatology HCPs (25% physicians) with an average of 8 years caring for patients with psoriatic disease (PsD). Results from these surveys revealed challenges in the comprehensive management of PsD. For example, 72% of dermatology HCPs were unsure how many of their psoriasis (PsO) patients had been diagnosed with PsA. One-half of rheumatology HCPs listed “differentiating PsO from other skin conditions” as a top challenge in managing patients with PsD, and 54% of dermatology HCPs answered “differentiating PsA from other joint pain conditions.” Only 36% of rheumatology HCPs and 12% of dermatology HCPs reported high confidence in performing these actions. Only approximately one-fourth of survey respondents reported that they always educate their PsA/PsO patients about the risks and symptoms of comorbid PsD. PsO screening practices among rheumatology HCPs and PsA screening practices among dermatology HCPs were inadequate, with one-fifth not screening at all (Figure 1).

Survey data also revealed that collaboration between these specialties is inadequate. Less than one-half of rheumatology HCPs (48%) reported that they collaborate with a dermatologist as soon as a PsA patient exhibits skin symptoms. Only 58% of dermatology HCPs reported that they collaborate with a rheumatologist as soon as a PsO patient exhibits joint symptoms. Only 34% of rheumatology HCPs collaborated with dermatologists in the management of their PsA patients with diagnosed PsO or complaints of skin symptoms; only 50% of dermatology HCPs collaborated with rheumatologists in the management of their PsO patients with diagnosed PsA or complaints of joint symptoms. Suboptimal proportions of respondents were implementing specific collaborative strategies prior to the educational session (Figure 2). The resources most frequently reported to be needed to adopt these strategies were additional education and updated technology/electronic medical record (EMR) systems. The most commonly reported areas rheumatology and dermatology teams planned to address following the educational session were early screening and identification, timely referrals, and improved co-management between these specialty teams.

Conclusion: These survey findings reveal suboptimal screening for PsD and inadequate collaboration between rheumatology and dermatology care teams in the management of this disease. Future educational initiatives and real-world system changes are needed to further close these gaps in care.

Supporting image 1

Supporting image 2


Disclosures: E. Siegel, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Eli Lilly, Janssen, UCB; A. Garg, AbbVie/Abbott, Janssen, Pfizer, UCB, Asana Biosciences, Incyte; J. Carter, None; L. Simone, None; M. Nelson, None.

To cite this abstract in AMA style:

Siegel E, Garg A, Carter J, Simone L, Nelson M. Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/assessment-of-perceptions-and-practices-regarding-the-collaborative-management-of-patients-with-psoriatic-arthritis-among-us-dermatology-and-rheumatology-teams/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-perceptions-and-practices-regarding-the-collaborative-management-of-patients-with-psoriatic-arthritis-among-us-dermatology-and-rheumatology-teams/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology